Treatment | ||
---|---|---|
Patients | Infliximab | Etanercept |
No. | 32 | 17 |
Age (years)a | 56.7 (23.5–80.9) | 55.3 (23.2–70.4) |
Female/male | 25/7 | 10/7 |
Duration of disease (years)a | 12.9 (3.0–55.5) | 13.7 (2.5–41.0) |
Serum CRP at baseline (mg/l)a | 20 (1–84) | 36 (1–85) |
Serum COMP at baseline (u/l)a | 11.3 (5.5–19.2) | 12.2 (8.1–29.7) |
DAS28 at baselinea | 5.3 (2.4–8.1) | 5.9 (3.7–7.5) |
HAQ at baselinea | 1.4 (0.4–2.8) | 1.6 (0.3–2.8) |
Monotherapy/combination therapy 5/27 | 3/14 | |
Prednisolone/no prednisolone | 20/12 | 11/6 |
ACR20 response at 3 months | 16 (50%) | 11 (65%) |